Formulation and evaluation of metformin hydrochloride sustained-release and empagliflozin immediate-release bilayer tablets
Abstract
Objective: The present study aimed to formulate and evaluate bilayer tablets containing sustained-release Metformin hydrochloride and immediate-release Empagliflozin for the management of Type 2 diabetes.
Methods: The wet granulation technique was employed to formulate a sustained-release Metformin HCl layer and an immediate-release Empagliflozin layer. The impact of varying concentrations of independent variables (HPMCK100M and Carbopol 971P) on drug release at different times was evaluated using a 2-factor central composite design (CCD)with five central replicates.The formulation was optimized using responsesurface methodology (RSM) through CCD, and optimal levels of polymers were determined using surface plots and response optimizer. In-vitro release data observed from the optimized formulation were subjected to pre- and post-compression analysis and fitted into various drug release kinetic models.
Results: Using response surface methodology (RSM), the optimized formulation contained 17.9% HPMCK100M and 3.8% Carbopol, respectively. Various parameters were noted: hardness, 21.33kg/cm²; friability, 0.23%; and uniformity of content for empagliflozin (98.23%), whichwas within the limit.The assay percentages of metformin and empagliflozin were 95.27% and 96%, respectively. In vitro drug release at 1, 6, 10, and 12 hours is 20.08%, 67.02%, 87.06%, and 97.52%, respectively, which is comparable to the predicted drug release by RSM.The optimized model accurately predicted the drug…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.